OCULAR DISEASE AND EARLY ONSET MYOPIA
Dr Jessica Mountford
Brian King Fellow &
Head of Functional Molecular Vision Group
Lions Eye Institute, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | November 2024
Dr Jessica Mountford received her highly ranked PhD from Monash University, Melbourne, in 2012, in the field of biochemistry and clinical haematology. Her work investigating novel ways to prevent thrombosis, a leading cause of heart attack and stroke, led to a first author publication in Nature Communications.
Following this, Dr Mountford relocated to Perth and went on to complete two post-doctoral appointments at the University of Western Australia, where she began research on the comparative evolution of visual and non-visual opsin across species of vertebrate, from the primitive lamprey to human.
During this period Dr Mountford began researching novel genetic variants associated with myopia development. With Adjunct Research Fellow appointments held at La Trobe University in Melbourne, and the University of Western Australia, Dr Mountford is currently the 6th Brian King Fellow and the Head of the Functional Molecular Vision Group at the Lions Eye Institute in Perth where she researches both the genetic and environmental factors involved in the development of early-onset myopia.
Dr Mountford has successfully established Western Australia’s first and only ocular genetic screening platform using zebrafish and utilises this model to help elucidate some of the complex gene-environment interactions responsible for the development of myopia.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Biological interactions of extracellular vesicles
Raluca Ghebosu graduated from the University of Queensland with a Bachelor of Arts/Bachelor of Science with majors in Japanese and Biomedical Science (2018-2021). She then completed her Bachelor of Science (Honours) with the School of Biomedical Sciences at the University of Queensland in 2022, before pursuing a PhD with A/Prof. Joy Wolfram at the Australian Institute for Bioengineering and Nanotechnology.
